Mezzion Pharma Co.Ltd (KQ:140410) — Market Cap & Net Worth
Market Cap & Net Worth: Mezzion Pharma Co.Ltd (140410)
Mezzion Pharma Co.Ltd (KQ:140410) has a market capitalization of $429.17 Million (₩633.28 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13136 globally and #378 in its home market, demonstrating a 0.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mezzion Pharma Co.Ltd's stock price ₩74100.00 by its total outstanding shares 8546310 (8.55 Million). Also see 140410 total assets for a full breakdown of the balance sheet.
Mezzion Pharma Co.Ltd Market Cap History: 2015 to 2026
Mezzion Pharma Co.Ltd's market capitalization history from 2015 to 2026. Data shows growth from $53.19 Million to $429.17 Million (21.27% CAGR). Also see 140410 cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Mezzion Pharma Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$234.31 Billion | 0.18% | #102 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$234.31 Billion | 0.18% | #102 of 1384 |
Weight: Mezzion Pharma Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mezzion Pharma Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mezzion Pharma Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Mezzion Pharma Co.Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
Mezzion Pharma Co.Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $44.40 Million | $8.75 Billion | -$12.98 Billion | 0.01x | N/A |
| 2017 | $77.03 Million | $5.59 Billion | -$14.88 Billion | 0.01x | N/A |
| 2018 | $177.61 Million | $19.09 Billion | -$18.88 Billion | 0.01x | N/A |
| 2019 | $369.32 Million | $18.93 Billion | -$23.25 Billion | 0.02x | N/A |
| 2020 | $339.39 Million | $28.63 Billion | -$13.83 Billion | 0.01x | N/A |
| 2021 | $419.13 Million | $26.65 Billion | -$13.60 Billion | 0.02x | N/A |
| 2022 | $75.29 Million | $30.73 Billion | -$36.30 Billion | 0.00x | N/A |
| 2023 | $225.88 Million | $31.72 Billion | -$12.73 Billion | 0.01x | N/A |
| 2024 | $178.67 Million | $8.61 Billion | -$19.48 Billion | 0.02x | N/A |
| 2025 | $521.83 Million | $7.91 Billion | -$34.93 Billion | 0.07x | N/A |
Competitor Companies of 140410 by Market Capitalization
Companies near Mezzion Pharma Co.Ltd in the global market cap rankings as of September 18, 2026. Review 140410 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Mezzion Pharma Co.Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5605 globally with a market cap of $2.37 Billion USD ( ₩3.50 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8267 globally with a market cap of $1.16 Billion USD ( ₩1.71 Trillion KRW).
- Komipharm International Co. Ltd (KQ:041960): Ranked #13903 globally with a market cap of $370.23 Million USD ( ₩546.32 Billion KRW).
- Caregen Co.Ltd (KQ:214370): Ranked #14978 globally with a market cap of $297.04 Million USD ( ₩438.31 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5605 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.37 Billion | ₩163500.00 |
| #8267 | ST Pharm Co.Ltd | KQ:237690 | $1.16 Billion | ₩91900.00 |
| #13903 | Komipharm International Co. Ltd | KQ:041960 | $370.23 Million | ₩9450.00 |
| #14978 | Caregen Co.Ltd | KQ:214370 | $297.04 Million | ₩40800.00 |
Mezzion Pharma Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Mezzion Pharma Co.Ltd's market cap moved from $53.19 Million to $ 429.17 Million, with a yearly change of 21.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩429.17 Million | -17.76% |
| 2025 | ₩521.83 Million | +192.06% |
| 2024 | ₩178.67 Million | -20.90% |
| 2023 | ₩225.88 Million | +200.00% |
| 2022 | ₩75.29 Million | -82.04% |
| 2021 | ₩419.13 Million | +23.49% |
| 2020 | ₩339.39 Million | -8.10% |
| 2019 | ₩369.32 Million | +107.93% |
| 2018 | ₩177.61 Million | +130.58% |
| 2017 | ₩77.03 Million | +73.48% |
| 2016 | ₩44.40 Million | -16.52% |
| 2015 | ₩53.19 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Mezzion Pharma Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $429.17 Million USD |
| MoneyControl | $429.17 Million USD |
| MarketWatch | $429.17 Million USD |
| marketcap.company | $429.17 Million USD |
| Reuters | $429.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more